Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | BRS3 | P32247 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26351716 | 0.88 | ESR1 (0.39) | ESR1HRH3CYP1A2CYP2D6HTR2A | |
| SCHEMBL19822052 | 0.84 | ESR1 (0.39) | ESR1HRH3CYP1A2CYP2D6HCRTR1 | |
| SCHEMBL13910813 | 0.81 | HRH3 (0.41) | ESR1HRH3CYP1A2CYP2D6HCRTR1 | |
| SCHEMBL10223944 | 0.80 | ESR1 (0.45) | ESR1HRH3CYP1A2CYP2D6ALDH1A1 | |
| SCHEMBL2717171 | 0.79 | HRH3 (0.34) | HRH3CYP1A2CYP2D6HTR2AKCNH2 | |
| SCHEMBL2714130 | 0.79 | HRH3 (0.34) | HRH3CYP1A2CYP2D6HTR2AKCNH2 | |
| SCHEMBL4550766 | 0.79 | LOXL2 (0.36) | HRH3CYP1A2CYP2D6HTR2AKCNH2 | |
| SCHEMBL12776135 | 0.79 | ESR1 (0.41) | ESR1HRH3CYP1A2CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL2713568 | 0.78 | LOXL2 (0.38) | HRH3CYP1A2CYP2D6HTR2AKCNH2 | |
| SCHEMBL18924439 | 0.78 | HRH3 (0.34) | HRH3CYP1A2CYP2D6HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189826-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189826-B2 | Heterocyclic compounds and methods of use | HRAS, VHL, ESRRB | ESR1 101/4885HRH3 1016/4885CYP1A2 1796/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | ESR1 101/4885HRH3 1016/4885CYP1A2 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.